TwinSolution Technology recently filed for listing on the STAR Market, with Huatai United Securities as the sponsor. According to Yole data and the company's prospectus, its chip testing interface revenue ranked first in mainland China in 2024, with customers including NVIDIA, Apple and other well-known enterprises. Financial data shows the company's 2024 revenue was RMB 331 million, with a three-year compound annual growth rate of 41.54%, though net profit experienced fluctuations. The IPO proceeds are intended primarily for construction of testing interface and probe card production bases, R&D center projects, and working capital supplementation.
On January 5, 2026, SKB BIO-B(06990.HK) issued an announcement stating that its core product sacituzumab govitecan (SAC-TMT) in combination with pembrolizumab for the first-line treatment of specific PD-L1-positive locally advanced or metastatic non-small cell lung cancer has been granted Breakthrough Therapy Designation by the NMPA. This designation supports subsequent conditional approval and priority review applications to accelerate the launch of the indication. Previous relevant Phase 3 clinical trials have shown significant clinical benefits, and the product has accumulated five Breakthrough Therapy Designations, with three indications approved in China and two included in medical insurance. The company and MSD are also advancing multiple clinical studies globally, while the announcement reminds that the development and commercialization of unapproved indications are subject to uncertainties.
EACON Group recently filed another listing application with the Hong Kong Stock Exchange, with Guotai Haitong Securities as the sole sponsor. According to Frost & Sullivan, the company is China's largest provider of autonomous driving solutions for mining areas by number of active mining trucks and 2024 revenue. The prospectus shows 2024 revenue of RMB 986 million and a three-year compound annual growth rate of 305.8%, though net losses continued to widen during the reporting period.
On December 30, 2025, Insilico Medicine, hailed as "the first AI-driven pharmaceutical stock on the Hong Kong stock market" and a strategic investment of the Hong Kong Investment Corporation Limited (HKIC), was listed on the Main Board of the Hong Kong Exchanges and Clearing Limited (HKEX). With a total fundraising of HK$2.277 billion, it has claimed the title of the largest IPO in the biopharmaceutical sector of the Hong Kong stock market in 2025, and its share price delivered an impressive performance on the debut day. It is reported that Biren Technology, another portfolio company of HKIC, is also set to list on the HKEX on January 2, 2026, which indicates that the effectiveness of HKIC’s diversified strategic investment layout continues to unfold.
